We have compared the prevalence of asthma, bronchial hyperresponsiveness (BHR) 
We have compared the prevalence of asthma, bronchial hyperresponsiveness (BHR) , and atopy in relation to parental smoking in children aged 7 to the day of the examination. Those children who gave an affirmative answer to the question: "Has the child ever had asthma?" were regarded as having asthma. A complete history of each parent's smoking habits from the child's birth to the date of the clinical examination was recorded prior to the SPT and the bronchial challenge. In addition, the accompanying parent was asked about the mother's smoking habits during pregnancy. The number of cigarettes smoked was not recorded.
Skin Prick Test and Bronchial Challenge Test
The SPT were performed on 556 of the attending 620 children who attended the examination using allergen-coated lancets (Phazet, Pharmacia, Uppsala, Sweden).'2 Eight allergens were used: birch, timothy grass pollen, mugwort, Dermatophagoides pteronyssinus, Cladosporium, horse, cat dander, and dog dander.
Histamine and saline solution were used as positive and negative controls. The volar aspect of the right forearm was used and the results were recorded after 15 min. The wheal size was recorded as the mean of the long axis and its perpendicular and was regarded as positive if it was -3 mm. Children who had a positive reaction to at least one of the SPTs were considered to have atopy regardless of the size of erythema.
Spirometry was performed using a pneumotachograph (Vitalograph, Birmingham, UK) that was calibrated daily to 5 L using a 1-L syringe. The test was accepted if the difference between the best and the second best test varied by less than 5% or 100 mL, whichever was larger. Methacholine challenge was performed using a shortened version of the protocol suggested by Cockcroft et al13 and Kongerud and Soyseth.'4 All the children whose baseline FEVy was >-70% of predicted'5 were invited to perform the challenge test. If there was no history of asthmatic symptoms and the FEVy was >80% of predicted, the inhalation started at 2.0 mg/mL. Otherwise the initial concentration was 0.125 mg/mL.
The concentration was increased fourfold unless the FEVI fell by more than 10% from one concentration to the next. Then the concentration of methacholine was doubled from one inhalation to the next. It was also doubled if the FEV, had decreased to less than 90% of baseline. The test was continued until a decrease from baseline of 20% or the maximum concentration of 32.0 mg/mL was reached.
If the FEVI was less than 70% of predicted,'5 the child was asked to perform a reversibility test. After two inhalations of 0.1 mg of salbutamol (Ventoline), a second spirometry measurement was carried out 5 min later. The response to the methacholine challenge was expressed as PC20: ie, the concentration that caused a fall in FEV, of 20% from baseline calculated by linear interpolation on the log-linear dose-response curve. A subject was regarded as having BHR if the PC20 was -8 mg/mL or the FEV, increased by more than 10% at the reversibility test.
Assessment of Exposure to ETS
The following indices of exposure to ETS were used in the analyses: (1) Maternal: MPRE=1 if the mother smoked for more than 3 months during pregnancy, otherwise MPRE=O; MPOST= 1 if the mother had ever smoked after her child's birth, otherwise MPOST=O; MPOST was divided into three subclasses: (1.1) MO1=1 if the mother smoked during the child's first year of life, otherwise M01=0; (1.2) MCUR=1 if the mother was a current smoker at the time of the investigation, otherwise MCUR=0; (1.3) MHIGH=1 if the mother had smoked for more than 7 years, otherwise MHIGH=0. (2) Paternal smoking was classified accordingly as P01, PCUR, PHIGH, and FEVER if the father had ever smoked after the child's birth.
Statistical Analyses
Univariate associations were investigated using simple x2 statistics for categorical data and t tests for continuous data using a statistical package (SYSTAT). 16 The following covariates were regarded as potential confounders to each of the three outcomes: age (at the time of the cross-sectional survey), gender, FAM, and BTY. The association among each of these covariates and asthma, atopy, and BHR was investigated separately and entered in the initial multivariate analyses if the univariate associations revealed a p value of 0.25 or less. '7 Since the exposure indices were mutually correlated, their relationship to each of the outcomes was investigated using stratified analysis (Mantel-Haenszel test).'8 The confidence intervals were estimated as suggested by Robins et al."9 The strategy of the bivariate analyses was as follows: (1) compare the effect of MPOST stratified for MPRE and vice versa. (2) Compare the effect of MOI and MCUR separately, stratified for MHIGH, and, conversely, the effect of MHIGH after the stratification of MOI and MCUR, respectively. Finally, (3) investigate the effect of exposure to paternal ETS as described in (2) .
Finally, the effects of the significant indices of exposure on each of the outcome variables obtained from the bivariate analyses were investigated in multivariate analyses by logistic regression using a module (LOGIT) of our statistical package (SYSTAT).'0 Backward model reduction was performed as suggested by Lemeshow and Hosmer.21 The effect of concurrent maternal and paternal smoking was investigated by including the product-term MPOSTXFEVER.
RESULTS
Of the 620 subjects who participated in the crosssectional examination, 573 (92.4%) performed spirometry and BHR was assessed in 529 (85.3%) using a methacholine challenge or reversibility test. The characteristics of the different subgroups are given in Table 1 . The relationship among BHR, atopy, and age is shown in Figure 1 . After stratification by age, the odds ratio (OR) of having BHR was 3.4 (95% confidence interval [CI], 2.0-6.0) in atopic children compared with nonatopic children.
The prevalence of parental smoking, including prenatal maternal smoking, is shown in Figure 2 . The prevalence of maternal smoking increased from 37.9% during pregnancy to 45.3% at the time of the investigation, whereas the prevalence of paternal 
DISCUSSION
In this study, we found that the prevalence of asthma was increased in children whose mothers had a history of postnatal smoking compared with children with never-smoking mothers. A significant decreased prevalence of atopy was associated with prenatal maternal smoking. The data also indicated that the prevalence of maternal smoking increased from pregnancy to the date of investigation contrary to the prevalence of smoking among Norwegian women in the age range 20 to 34 years in the same period.22 It therefore seems likely that mothers try to avoid cigarette smoking during pregnancy, whereas their smoking rates increase after the delivery of the child.
Although a significant association was found between postnatal maternal smoking and asthma, we were not able to demonstrate any association between Weitzman and coworkers24 found that the OR of developing asthma during the first year of life was 2.6 in children with smoking mothers as compared with the children of nonsmoking mothers. The similar associations between asthma and maternal smoking were estimated at 2.8 in children aged 3 to 4 years25 and 2.5 in children 7 to 9 years of age.26 In none of these studies were adjustments for previous exposure or cumulative exposure made. In our study, the OR of asthma was 2.8 in children whose mothers were ever smokers compared with never-smoking mothers; ie, in agreement with all the studies cited above. Hence, it seems likely that the increased risk of childhood asthma associated with maternal smoking is uniform across the age-exposure strata. Since postnatal maternal smoking was unrelated to BHR and atopy, we hypothesize that childhood asthma is provoked by exposure to maternal tobacco smoke rather than being induced by ETS.
Prenatal maternal smoking appeared to have a protective effect on the development of atopy in the offspring. A causal interpretation of this result is, however, unlikely. A comparison of cord serum revealed increased IgE and IgD levels in the offspring of mothers who were smokers compared with mothers who were nonsmokers during pregnancy,27 ie, apparently in conflict with our result. Although a parental history of asthma or hay fever was included as a covariate in the analyses, we believe that our result might be distorted due to the selective avoidance of tobacco smoking during pregnancy. The observation that the prevalence of maternal smoking increased from pregnancy to the time of the cross-sectional survey should support this explanation. Furthermore, the primary health care centers offer future mothers checkups every month during pregnancy. The attendance rates in these surveys are high and information about the effects of passive smoking on the fetus is emphasized at these follow-ups. It could be that those mothers with an increased risk of ETS-related disorders quit smoking. However, our results indicate that parental smoking does not increase allergy sensitization in children. This view is also supported by other studies. 9"10 When it comes to BHR, the association with the different kinds of ETS exposure was close to the zero effect, thereby indicating that ETS does not induce structural changes in the bronchial mucosa. 28 Other investigators have associated BHR in childhood with exposure to maternal smoking.5'6 These conflicting results could also be explained by the selection bias caused by selective avoidance of cigarette smoking among the parents.
In conclusion, our results indicate that postnatal maternal smoking increases the prevalence of asthma in the offspring without inducing BHR or enhancing sensitization to allergens. Thus, ETS exposure appears to provoke childhood asthma without inducing the disease.
